Skip to main
ALKS

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 43%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Alkermes PLC is positioned for revenue growth through 2030, primarily driven by the acquisition of Lumryz, which is anticipated to generate annualized sales of approximately $265-$275 million by 2025 and has significant potential in niche markets. The positive outlook is bolstered by ongoing investments in the development of alixorexton and the continued growth of existing products like Aristada and Lybalvi, supporting expected earnings per share (EPS) growth. Additionally, the strategic acquisition of Lumryz enhances Alkermes’s commercial opportunities without adversely affecting its balance sheet, thereby strengthening both its short- and medium-term financial prospects.

Bears say

Alkermes PLC faces a challenging financial outlook due to anticipated declines in Lumryz sales following the loss of exclusivity in 2037, compounded by competition from multiple orexin 2 receptor agonists that may hinder overall growth. Furthermore, key risks such as the erosion of its royalty business, early-stage efficacy concerns regarding its orexin data, and significant exposure to Medicaid present additional pressures on earnings. Analysts have adjusted the company’s pricing targets downward, reflecting a more conservative EBITDA multiple and signifying skepticism regarding the long-term competitiveness and profitability of its core products.

Alkermes (ALKS) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 43% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 14 analysts, Alkermes (ALKS) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.